Publications by authors named "Leroy Okonta"
Article Synopsis
- Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved in November 2021 for use in virally suppressed adults in England and Wales, and the evaluation of its delivery processes took place across 12 clinics.* -
- A total of 518 adults were approved for CAB + RPV LAI from February 2022 to December 2023, with 423 receiving at least one injection; the treatment had a median duration of 7.5 months and a high adherence rate of 97% for timely injections.* -
- Results indicated only 0.7% experienced virological failure and 6% discontinued treatment, showcasing that effective clinic protocols and
Background And Purpose: Locally recurrent rectal cancer (LRRC) is associated with considerable morbidity, poor quality of life and an overall survival of 9 months. The non-operative treatment of LRRC is an understudied area, there is no consensus on management in this setting. We aim to perform a retrospective, multicentre analysis of patients treated with SABR reirradiation.
View Article and Find Full Text PDFPurpose: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet been implemented in routine clinical practice. Following a previous internal review in which two patients underwent lengthy hospitalisations whilst receiving capecitabine, and were subsequently found to be DPD deficient, we initiated routine DPYD genotyping prior to starting capecitabine.
View Article and Find Full Text PDF